Professional Documents
Culture Documents
NATF ACC Healthcare Provider May 2020
NATF ACC Healthcare Provider May 2020
Brand name
Warfarin*
*Coumadin® was
discontinued in
April 2020. Dabigatran Rivaroxaban Apixaban Edoxaban Betrixaban
Generic Yes No No No* No No
*The FDA approved
a generic in
December 2019, but
it’s not available yet.
FDA-approved Stroke prevention Stroke prevention Stroke prevention Stroke prevention Stroke prevention VTE prevention
indications in Afib in nonvalvular in nonvalvular in nonvalvular in nonvalvular in hospitalized
Stroke prevention Afib Afib Afib Afib acute medically ill
in those with VTE treatment VTE treatment VTE treatment VTE treatment patients
heart valve VTE prevention in VTE prevention in VTE prevention in
replacements patients already patients already patients already
VTE treatment treated for a treated for a treated for a
VTE prevention blood clot blood clot blood clot
VTE prevention VTE prevention VTE prevention
after hip after hip and after hip and
replacement knee replacement knee replacement
surgery surgery surgery
VTE prevention
during
hospitalization
and after
discharge in
adults with acute
medical illness
Prevention of
major CV events
in patients with
CAD and PAD*
*In combination with
aspirin
Drug image and Doses vary 75 mg, 110 mg, 2.5 mg, 10 mg, 2.5 mg or 5 mg 15 mg, 30 mg, or 40 mg or 80 mg
available dosages or 150 mg capsule 15 mg, or 20 mg tablet 60 mg tablet capsule
tablet
Acute medical illness: Conditions such as pneumonia, stroke, heart failure, CAD: Coronary artery disease
infection, or inflammatory disease Major cardiovascular (CV) events: CV death, heart attack, and stroke
Afib: Atrial fibrillation (nonvalvular Afib refers to Afib in patients without PAD: Peripheral artery disease
mechanical heart valves)
VTE: Venous thromboembolism